Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: ACTG1

Summary for ACTG1

Gene information	Gene symbol	ACTG1
	Ensembl ID	ENSG00000184009
	Entrez ID	71
	Gene name	actin gamma 1
	Synonyms	ACTG\|DFNA20\|DFNA26
	Gene type	protein_coding
	UniProtAcc	P63261

Top

Dataset with differentially expressed gene: ACTG1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-0.710149	5.35e-10
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-4.80455	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.954764	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.329986	4.10e-41
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.610318	5.91e-24
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.444821	2.79e-36
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	0.927729	1.86e-08
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.298877	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.328416	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.90055	4.75e-25
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	0.258809	1.91e-08
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.266695	3.19e-29
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.621606	4.66e-16
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.958773	6.49e-24
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.336636	6.07e-29
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	cDCs	-0.280994	3.63e-03
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.509947	1.83e-13
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.542208	1.78e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-1.26428	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.278362	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.46333	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.550457	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	0.639726	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Progenitors	-0.654849	1.53e-03
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-0.893739	4.07e-17
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	0.41484	3.18e-23
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	0.521372	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.65643	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	0.371007	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.395093	6.13e-14
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-1.10182	9.32e-12
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD4+ T cells	0.267693	2.57e-15
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.363676	5.25e-39
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-0.357978	2.60e-19
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	-0.42628	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.888613	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.865973	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.321289	1.44e-34
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	pre	Malignant cells	0.32097	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.370493	4.77e-17
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.330599	1.32e-38
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	1.1452	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.804584	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.916316	2.02e-12
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.637419	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Erythrocytes	-0.847027	1.99e-12
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-2.41677	1.43e-11
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.515471	6.47e-10
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD4+ T cells	-0.809791	5.54e-03
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	-0.322146	0.00e+00
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	-0.36909	3.03e-02
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.262991	3.23e-22
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.699711	0.00e+00
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	-0.372965	1.79e-24
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.323124	4.18e-19
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.477482	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	-0.281065	2.01e-22
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.522749	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.261993	2.11e-13
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	cDCs	-0.46017	5.76e-03
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-1.83947	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-0.450715	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-0.641302	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.860598	0.00e+00

Top

Expression of ACTG1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to ACTG1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating ACTG1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
ACTG1	hsa-miR-1825	94.4464	NM_001199954
ACTG1	hsa-miR-5195-3p	91.1806	NM_001199954
ACTG1	hsa-miR-145-5p	88.8444	NM_001199954
ACTG1	hsa-miR-4731-5p	88.4529	NM_001199954
ACTG1	hsa-miR-6515-3p	86.2137	NM_001199954
ACTG1	hsa-miR-10a-5p	85.0025	NM_001199954
ACTG1	hsa-miR-10b-5p	85.0025	NM_001199954
ACTG1	hsa-miR-3194-5p	83.9362	NM_001199954
ACTG1	hsa-miR-7151-3p	83.7097	NM_001199954
ACTG1	hsa-miR-624-3p	83.7086	NM_001199954
ACTG1	hsa-miR-1202	83.6473	NM_001199954
ACTG1	hsa-miR-3972	83.6473	NM_001199954
ACTG1	hsa-miR-561-5p	83.0094	NM_001199954
ACTG1	hsa-miR-503-3p	80.5791	NM_001199954

Page: 1

Top

Motifs and transcription factors (TFs) regulating ACTG1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
ACTG1	metacluster_111.6	GMEB1; GMEB2 (directAnnotation).
ACTG1	metacluster_132.4	MEF2B; MEF2B; MEF2B; MEF2B; MEF2C; MEF2C; MEF2D; MEF2D; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF (directAnnotation). SRF; SRF; SRF; SRF (inferredBy_Orthology).
ACTG1	hocomoco__MNX1_HUMAN.H11MO.0.D	MNX1 (directAnnotation).
ACTG1	transfac_pro__M02843	BBX (inferredBy_Orthology).
ACTG1	taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP	ELK1; TEF (directAnnotation).
ACTG1	taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2	ELK1; GCM1 (directAnnotation).
ACTG1	transfac_pro__M06350	ZNF449 (directAnnotation).
ACTG1	jaspar__MA1657.1	ZNF652 (directAnnotation).
ACTG1	tfdimers__MD00378	E2F1; NFIA; NFIC (directAnnotation).
ACTG1	transfac_pro__M06292	ZNF766 (directAnnotation).
ACTG1	transfac_pro__M06488	ZNF595 (directAnnotation).
ACTG1	transfac_pro__M06189	ZNF91 (directAnnotation).
ACTG1	transfac_pro__M04966	EP300 (directAnnotation).
ACTG1	taipale_tf_pairs__TEAD4_TCF3_NCAGGTGNGWATGYN_CAP_repr	TCF3; TEAD4 (directAnnotation).
ACTG1	taipale_tf_pairs__TEAD4_FIGLA_GGAATKNNCASSTG_CAP_repr	FIGLA; TEAD4 (directAnnotation).
ACTG1	taipale_tf_pairs__TEAD4_CLOCK_NCACGTGNNNNNNCATWCC_CAP_repr	CLOCK; TEAD4 (directAnnotation).
ACTG1	tfdimers__MD00061	E2F1; NR3C1 (directAnnotation).
ACTG1	transfac_pro__M05870	ZNF625 (directAnnotation).
ACTG1	cisbp__M00220	SNAI2 (directAnnotation).
ACTG1	tfdimers__MD00372	PITX3; STAT1; STAT2; STAT3; STAT4; STAT5A; STAT5B; STAT6 (directAnnotation).
ACTG1	taipale_tf_pairs__MYBL1_ONECUT2_NAACGGNNATYGANN_CAP_repr	MYBL1; ONECUT2 (directAnnotation).
ACTG1	swissregulon__hs__GMEB2	GMEB2 (directAnnotation).
ACTG1	metacluster_168.4	ZNF652 (directAnnotation).
ACTG1	transfac_pro__M06388	ZNF677 (directAnnotation).
ACTG1	taipale_tf_pairs__MGA_DLX3_AGGTGNTAATKR_CAP	DLX3; MGA (directAnnotation).
ACTG1	transfac_pro__M06175	ZNF140 (directAnnotation).
ACTG1	tfdimers__MD00493	MYB; NFE2L1 (directAnnotation).
ACTG1	transfac_pro__M06557	ZNF418 (directAnnotation).
ACTG1	transfac_public__M00040	ATF2 (directAnnotation).
ACTG1	transfac_pro__M06964	SALL4 (inferredBy_Orthology).
ACTG1	transfac_pro__M05464	SALL1 (directAnnotation).
ACTG1	kznf__ZNF184_Schmitges2016_RCADE	ZNF184 (directAnnotation).
ACTG1	transfac_pro__M04937	TCF12 (directAnnotation).
ACTG1	metacluster_140.7	NR2E1; NR2E3 (directAnnotation). NR2E1; NR2E1; NR2E1 (inferredBy_Orthology).
ACTG1	transfac_pro__M04860	RXRA (directAnnotation).
ACTG1	cisbp__M01737	FIGLA (inferredBy_Orthology).
ACTG1	transfac_pro__M06552	ZNF420 (directAnnotation).
ACTG1	metacluster_71.2	EPAS1 (directAnnotation).
ACTG1	hocomoco__PO5F1_HUMAN.H11MO.1.A	POU5F1 (directAnnotation).
ACTG1	metacluster_5.2	ZNF564 (directAnnotation).
ACTG1	transfac_pro__M00616	ZFHX3 (directAnnotation).
ACTG1	homer__VCAGGTRDRY_ZEB1	ZEB1 (directAnnotation).
ACTG1	tfdimers__MD00058	SMAD3; YY1 (directAnnotation).
ACTG1	taipale_tf_pairs__HOXB2_TBX21_NGGTGTGNNNNNTMATTWGCRN_CAP_repr	HOXB2; TBX21 (directAnnotation).
ACTG1	transfac_pro__M07435	TWIST1 (directAnnotation).
ACTG1	transfac_pro__M00799	MAX; MYC (directAnnotation).
ACTG1	metacluster_160.16	ZNF708 (directAnnotation).
ACTG1	homer__NNCACCTGCN_E2A	TCF3 (inferredBy_Orthology).
ACTG1	taipale_tf_pairs__TEAD4_FIGLA_GGAATKNNCASSTG_CAP	FIGLA; TEAD4 (directAnnotation).
ACTG1	cisbp__M00195	CIC (inferredBy_Orthology).

Page: 1 2 3 4 5 6 7

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
ACTG1	"Artenimol"	DB11638	small molecule
ACTG1	"Copper"	DB09130	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."